Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 301 in first-line KRAS G12C-mutant metastatic colorectal cancer
NL-OMON60027Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sotorasib, panitumumab, irinotecan, fluorouracil, folinic acid and 1 more in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Mar 2025; status: recruiting.
02
Drugs
sotorasibpanitumumabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON60027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60027.